Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyAvalon Prenatal Screening Coverage Update | OpenPa…
    Ask Trek AI about this page
    ModifiedAvalon Healthcare SolutionsPolicy AHS-G2035

    Prenatal Screening (Nongenetic)

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS-G2035 alerts

    Get alerted when Policy AHS-G2035 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of routine and risk-based biochemical and laboratory screening during pregnancy, including infectious disease, diabetes, hematologic, urinary, immunologic, and preterm-labor testing, subject to the member’s benefit plan and applicable government coverage policies.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyPrenatal Screening (Nongenetic)
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionDocument pregnancy status, gestational timing, screening indication, and relevant risk factors or symptoms when requesting prenatal screening.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    CPT code 87592 was removed because the screening addressed by the policy uses qualitative testing and 87592 represents quantitative testing.

    The policy was reviewed and updated for background, guidelines, recommendations, and evidence-based scientific references without modifying coverage criteria.

    CPT codes 84702, 84703, 84704, and 87389 were added during prior revisions.

    The policy was separated from genetic prenatal screening and renamed Prenatal Screening (Nongenetic) to address biochemical and infection screening only.

    15Routine prenatal screening services meeting coverage criteria
    3Explicitly noncovered testing situations
    24–28 weeksGestational window for routine diabetes screening and repeat Rh(D) antibody testing
    36–37 weeksRecommended gestational window for Group B streptococcal screening
    87592Quantitative testing code removed
    03/05/2026Latest ODM approval date

    Prenatal Screening Coverage Criteria

    Routine prenatal screening

    Routine prenatal screening meets coverage criteria for all pregnant individuals when the applicable test is performed according to the specified timing or frequency.

    Covered routine prenatal screening services

    • Antigen/antibody combination assay screening for HIV infection.
    • Screening for Chlamydia trachomatis infection.
    • Screening for Neisseria gonorrhoeae infection.
    • Triple panel screening (HBsAg, anti-HBs, and total anti-HBc) for hepatitis B.
    • Screening for syphilis.
    • Antibody screening for hepatitis C.
    • Screening for type 2 diabetes at the first prenatal visit.
    • Screening for gestational diabetes during gestational weeks 24–28, or at the first prenatal visit when risk factors are present.24–28 weeks
    • Determination of blood type, Rh(D) status, and antibody status during the first prenatal visit; repeat Rh(D) antibody testing at 24–28 weeks for unsensitized Rh(D)-negative individuals unless the biological father is known to be Rh(D)-negative.First prenatal visit; repeat at 24–28 weeks when applicable
    • Screening for anemia with a CBC or hemoglobin and hematocrit with mean corpuscular volume.
    • Screening for Group B streptococcal disease once per pregnancy, recommended during gestational weeks 36–37.Once per pregnancy; recommended at 36–37 weeks
    • Urinalysis and urine culture.
    • Rubella antibody testing.
    • Testing for varicella immunity.
    • Screening for tuberculosis in pregnant individuals deemed to be at high risk for TB.

    High-risk third-trimester infection rescreening

    Coverage requires continued high risk of infection.

    Third-trimester infection rescreening

    • The individual is pregnant and remains at continued high risk of infection, such as having new or multiple sex partners, a history of sexually transmitted infections, or past or current injection drug use.Third trimester
    • Covered repeat infection screening

      • Repeat screening for Chlamydia trachomatis infection.
      • Repeat screening for Neisseria gonorrhoeae infection.
      • Repeat screening for syphilis infection.

    Fetal fibronectin for symptomatic preterm labor

    Coverage requires both a qualifying pregnancy and symptomatic presentation.

    Fetal fibronectin assay

    • Qualifying pregnancy

      • The individual has a singleton pregnancy.
      • The individual has a twin pregnancy.
    • The individual presents in the ambulatory setting with signs or symptoms of preterm labor.

    hCG testing in uncomplicated pregnancy

    The following service does not meet coverage criteria in the stated circumstance.

    Noncovered hCG testing

    • The individual has a normal pregnancy without complications.Normal, uncomplicated pregnancy
    • Human chorionic gonadotropin (hCG) hormone testing is requested.

      hCG testing does not meet coverage criteria in this circumstance.

    Salivary estriol risk assessment

    The following service does not meet coverage criteria because available published scientific literature does not confirm that the testing is required and beneficial for diagnosis and treatment.

    Noncovered salivary estriol monitoring

    • Serial monitoring of salivary estriol levels is used as a technique for risk assessment of preterm labor or delivery.Serial salivary estriol monitoring

      This service does not meet coverage criteria because supporting published scientific literature is lacking.

    Human chorionic gonadotropin (hCG) hormone testing does not meet coverage criteria for individuals with a normal pregnancy without complications.

    Serial monitoring of salivary estriol levels does not meet coverage criteria when used to assess the risk of preterm labor or delivery. The policy cites a lack of published scientific literature confirming that this testing is required and beneficial for diagnosis and treatment.

    Routine screening for bacterial vaginosis does not meet coverage criteria for asymptomatic pregnant individuals, including those at high risk for preterm delivery. Individuals with symptoms should be evaluated and treated.

    Routine screening for Trichomonas vaginalis does not meet coverage criteria for asymptomatic pregnant individuals. Individuals who report symptoms should be evaluated and treated.

    Routine HSV-2 serologic screening does not meet coverage criteria for asymptomatic pregnant individuals. Type-specific serologic testing may be useful in selected circumstances, such as evaluating recurrent or atypical genital symptoms or lesions, a clinical diagnosis without laboratory confirmation, or a partner with genital herpes. Routine serial HSV cultures are not indicated in the third trimester for individuals with recurrent genital herpes.

    Routine Zika virus testing is not recommended for asymptomatic pregnant patients who lived in or traveled to the United States or its territories, or who traveled to an area with current or past Zika virus transmission. Testing may be considered after travel to an area with an active CDC Zika Travel Health Notice, with NAAT testing up to 12 weeks after travel. If testing is pursued after travel to an area with current or past transmission outside the United States and its territories, NAAT may also be performed up to 12 weeks after travel. Symptomatic patients with qualifying travel or sexual exposure should have specimens collected as soon as possible, up to 12 weeks after symptom onset, according to the applicable testing recommendations.

    Applicable Laboratory Coding

    Obstetric panel and component codesCPT
    80055Obstetric panel
    80081Obstetric panel (includes HIV testing)
    85025Blood count, complete (CBC), automated and automated differential WBC count
    85027Blood count, complete (CBC), automated
    85004Automated differential WBC count
    85007Blood smear, microscopic examination with manual differential WBC count
    85009Blood count; manual differential WBC count, buffy coat
    87340Hepatitis B surface antigen (HBsAg)
    86762Antibody, rubella
    86592Syphilis test, non-treponemal antibody; qualitative (e.g., VDRL, RPR, ART)
    1–10 of 14
    1/2
    Urinalysis codesCPT
    81001Urinalysis by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy
    81002Urinalysis by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy
    81003Urinalysis by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy
    81007Urinalysis; bacteriuria screen, except by culture or dipstick
    81015Urinalysis; microscopic only
    Other applicable prenatal screening procedure codesCPT
    82677Estriol
    82731Fetal fibronectin, cervicovaginal secretions, semi-quantitative
    82947Glucose; quantitative, blood (except reagent strip)
    82950Glucose; post glucose dose (includes glucose)
    82951Glucose; tolerance test (GTT), 3 specimens (includes glucose)
    82962Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use
    83036Hemoglobin; glycosylated (A1C)
    84702Gonadotropin, chorionic (hCG); quantitative
    84703Gonadotropin, chorionic (hCG); qualitative
    84704Gonadotropin, chorionic (hCG); free beta chain
    1–10 of 12
    1/2
    Applicable CPT/HCPCS Procedure CodesmixedCovered
    81007Urinalysis; bacteriuria screen, except by culture or dipstick
    81015Urinalysis; microscopic only
    82677Estriol
    82731Fetal fibronectin, cervicovaginal secretions, semi-quantitative
    82947Glucose; quantitative, blood (except reagent strip)
    82950Glucose; post glucose dose (includes glucose)
    82951Glucose; tolerance test (GTT), 3 specimens (includes glucose)
    82962Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use
    83036Hemoglobin; glycosylated (A1C)
    84702Gonadotropin, chorionic (hCG); quantitative
    1–10 of 60
    1/6
    Preconception A1C target
    TargetA1C <6.5% (48 mmol/mol)
    ContextPreconception counseling for individuals with preexisting diabetes who are planning pregnancy
    PurposeReduce the risk of congenital anomalies, preeclampsia, macrosomia, preterm birth, and other complications
    Fetal fibronectin gestational age
    Gestational age24 to 34 6/7 weeks
    Clinical circumstanceSigns and symptoms of preterm labor

    Documentation and Provider Actions

    Documentation Required

    Document Pregnancy Status, Timing, and Indication

    Document the patient’s pregnancy status, gestational timing, and clinical indication in the record when requesting prenatal screening.

    • Record that the patient is pregnant.
    • Document gestational age or timing of the requested screening.
    • State the clinical indication for the test.
    Documentation Required

    Document Indication and Risk Factors

    Document the indication and relevant risk factors supporting prenatal screening or repeat testing, including exposure history, symptoms, and prior testing.

    • Record pregnancy status and gestational timing.
    • Document the indication and relevant risk factors, such as new or multiple sex partners, sexually transmitted infections, injection drug use, HIV exposure, or other ongoing infection risk.
    • Document relevant travel or exposure history, symptoms, and fetal-imaging findings when applicable.

    Policy Background

    Prenatal screening is testing of asymptomatic or healthy pregnant individuals to identify infectious diseases and other conditions that may affect the pregnancy or pregnant individual. The policy addresses routine and risk-based screening for conditions including anemia, blood type and antibody status, glucose abnormalities, asymptomatic bacteriuria or proteinuria, and infectious diseases. Rh(D) and repeat antibody testing help identify alloimmunization risk, while fetal fibronectin can help assess the likelihood of spontaneous preterm birth in symptomatic singleton or twin pregnancies. Screening is distinct from diagnostic testing, which is used to confirm or refute an abnormality.

    Terms and Abbreviations

    Screening
    TermScreening
    DefinitionTesting of asymptomatic or healthy individuals to search for a condition that may affect the pregnancy or individual
    Policy contextPrenatal screening includes testing to determine the health status of the pregnant individual and/or fetus
    Diagnostic testing
    TermDiagnostic testing
    DefinitionTesting used to confirm or refute true abnormalities in an individual
    DistinctionDiagnostic testing differs from screening, which searches for a condition in asymptomatic or healthy individuals
    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyPrenatal Screening (Nongenetic)
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionDocument pregnancy status, gestational timing, screening indication, and relevant risk factors or symptoms when requesting prenatal screening.
    SourceLink
    On This Page
    Prenatal Screening Coverage CriteriaApplicable Laboratory CodingDocumentation and Provider ActionsPolicy BackgroundTerms and Abbreviations
    Repeat screening for HIV infection.
    UseFetal fibronectin testing may be considered as part of the evaluation strategy
    HIV incidence threshold for third-trimester testing
    Annual incidence threshold≥1 per 1,000 individuals screened per year
    Testing timingConsider a second HIV test during the third trimester, preferably before 36 weeks’ gestation
    Applicable settingClinical settings meeting the HIV incidence threshold
    Tuberculosis prevalence threshold
    Population prevalence threshold100 per 100,000 population or higher
    ConditionTuberculosis prevalence in the general population
    Recommended actionSystematic screening for active tuberculosis should be considered for pregnant individuals as part of antenatal care
    Hepatitis C exception
    HCV positivity threshold<0.1%
    General approachPregnant individuals should be screened for hepatitis C
    ExceptionScreening exception applies in settings where HCV positivity is below 0.1%
  1. Include prior testing and treatment results, including prior screening, test-of-cure, or retesting information.
  2. Billing Rule

    Verify Code Selection and Performed Components

    Select the applicable individual or panel code and verify that all components required by the code were actually performed and documented.

    • Use the applicable obstetric panel code (80055 or 80081) only when its required components are included.
    • For urinalysis, select the code matching the performed method and microscopy status (81001, 81002, 81003, 81007, or 81015).
    • Use 82731 for fetal fibronectin, 82677 for estriol, and the applicable glucose, hCG, blood-count, and related individual-service codes when those services are performed.
    • Confirm that each billed component is supported by the laboratory record and clinical documentation.
    Denial Risk

    Routine hCG Testing Is Not Covered in an Uncomplicated Pregnancy

    Routine hCG hormone testing does not meet coverage criteria for individuals with a normal, uncomplicated pregnancy. Do not submit routine hCG testing without a covered clinical indication.

    • Applies to normal pregnancies without complications.
    • Noncovered hCG services include quantitative, qualitative, and free beta-chain hCG testing when performed routinely without a qualifying indication.
    Denial Risk

    Serial Salivary Estriol Monitoring Is Not Covered

    Serial monitoring of salivary estriol levels as a technique for assessing risk of preterm labor or delivery does not meet coverage criteria because published evidence has not established that the testing is required and beneficial.

    • Do not submit serial salivary estriol monitoring as routine risk assessment for preterm labor or delivery.
    • Estriol testing is listed under CPT 82677.

    Unsupported block type: documentation

    Documentation Required

    Symptomatic Preterm-Labor Evaluation

    For a singleton or twin pregnancy evaluated in the ambulatory setting with signs or symptoms of preterm labor, document the symptoms and perform the fetal fibronectin assay when clinically indicated.

    • Coverage applies to pregnant individuals with singleton or twin pregnancies.
    • Document the ambulatory setting and signs or symptoms of preterm labor.
    • Use CPT 82731 for fetal fibronectin in cervicovaginal secretions, semi-quantitative.
    Denial Risk

    Avoid Unsupported Routine Infection Screening

    Do not submit unsupported routine infection screening. Evaluate and treat symptomatic patients, while recognizing that routine screening is not supported for asymptomatic bacterial vaginosis, Trichomonas vaginalis, or HSV-2 serology.

    • Routine screening for bacterial vaginosis is not supported, including in asymptomatic pregnant individuals at high risk for preterm delivery.
    • Routine screening for Trichomonas vaginalis in asymptomatic pregnant individuals is not supported; evaluate and treat patients who report symptoms.
    • Routine HSV-2 serologic screening in asymptomatic pregnant individuals is not recommended.
    • Type-specific HSV serology may be useful for recurrent or atypical genital symptoms or lesions with a negative PCR or culture, an unconfirmed clinical diagnosis of genital herpes, or a partner with genital herpes.
    • Routine serial HSV cultures in the third trimester are not indicated solely because of a history of recurrent genital herpes.
    Documentation Required

    Zika Testing Requires Qualifying Circumstances

    Zika testing requires a qualifying travel, exposure, symptom, or fetal-imaging circumstance; routine testing is not recommended for asymptomatic pregnant patients without a qualifying circumstance.

    • For asymptomatic patients, document travel during pregnancy to an area with an active CDC Zika Travel Health Notice, or another qualifying exposure or fetal ultrasound finding consistent with congenital Zika infection.
    • For symptomatic patients, document symptom onset and exposure: testing is indicated after residence or travel to an area with an active Travel Health Notice, sex with someone with that exposure, or residence or travel to an area with current or past Zika transmission.
    • For symptomatic patients, collect specimens as soon as possible after symptom onset, up to 12 weeks after onset; test selection depends on the exposure circumstance and may include dengue and Zika NAAT and IgM testing on serum and Zika NAAT on urine.
    • For a fetus with prenatal ultrasound findings consistent with congenital Zika infection, document the relevant travel or sexual exposure and perform Zika NAAT and IgM on serum and NAAT on urine; consider amniotic-fluid testing if amniocentesis is performed as part of clinical care.
    • Document confirmatory testing requirements when applicable, including repeat NAAT after a positive result and PRNT when indicated by negative NAAT with positive IgM.
    CBC
    AbbreviationCBC
    Expanded termComplete Blood Count
    Laboratory categoryBlood count testing used in prenatal screening terminology
    FFN
    AbbreviationFFN
    Expanded termFetal fibronectin
    Clinical useTesting considered in the evaluation of symptomatic preterm labor
    EPSDT
    AbbreviationEPSDT
    Expanded termEarly and Periodic Screening, Diagnostic and Treatment
    Age contextUnder EPSDT, pediatric individuals are considered up to age 21
    GBS
    AbbreviationGBS
    Expanded termGroup B streptococcal disease
    Terminology categoryPrenatal screening terminology for group B streptococcal disease
    hCG
    AbbreviationhCG
    Expanded termHuman chorionic gonadotropin
    Testing contextThe policy addresses hCG hormone testing during pregnancy
    RhD
    AbbreviationRhD
    Expanded termRh blood group D antigen
    Prenatal testing contextRh(D) status and antibody status are part of routine prenatal screening
    NAAT
    AbbreviationNAAT
    Expanded termNucleic Acid Amplification Test
    Testing categoryA nucleic-acid-based testing method identified in the policy terminology
    Laboratory-developed test (LDT)
    DefinitionA test developed and performed by a laboratory
    Regulatory oversightRegulated by the Centers for Medicare and Medicaid Services as a high-complexity test under the Clinical Laboratory Improvement Amendments of 1988
    FDA statusNot approved or cleared by the FDA; FDA clearance or approval is not currently required for clinical use
    Obstetric panel
    DefinitionA bundled laboratory service containing specified prenatal laboratory components
    Core componentsCBC testing, hepatitis B surface antigen, rubella antibody, syphilis testing, RBC antibody screen, and ABO/Rh blood typing
    HIV-inclusive panelThe 80081 obstetric panel also includes HIV testing
    Panel codes80055 and 80081